RU2003115622A - METHOD FOR TREATING NEUROLOGICAL AND NEUROPSYCHOLOGICAL DISORDERS - Google Patents
METHOD FOR TREATING NEUROLOGICAL AND NEUROPSYCHOLOGICAL DISORDERSInfo
- Publication number
- RU2003115622A RU2003115622A RU2003115622/14A RU2003115622A RU2003115622A RU 2003115622 A RU2003115622 A RU 2003115622A RU 2003115622/14 A RU2003115622/14 A RU 2003115622/14A RU 2003115622 A RU2003115622 A RU 2003115622A RU 2003115622 A RU2003115622 A RU 2003115622A
- Authority
- RU
- Russia
- Prior art keywords
- use according
- inhibitors
- preceding paragraphs
- medicament
- manufacture
- Prior art date
Links
- 230000000926 neurological effect Effects 0.000 title claims 2
- 230000003557 neuropsychological effect Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 230000003001 depressive effect Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 101710151321 Melanostatin Proteins 0.000 claims 1
- 102400000064 Neuropeptide Y Human genes 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 1
- 208000005392 Spasm Diseases 0.000 claims 1
- 230000003044 adaptive effect Effects 0.000 claims 1
- 230000003542 behavioural effect Effects 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 claims 1
- 238000006731 degradation reaction Methods 0.000 claims 1
- 239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 238000012377 drug delivery Methods 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 206010016256 fatigue Diseases 0.000 claims 1
- 206010022437 insomnia Diseases 0.000 claims 1
- BPGXUIVWLQTVLZ-OFGSCBOVSA-N neuropeptide y(npy) Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 BPGXUIVWLQTVLZ-OFGSCBOVSA-N 0.000 claims 1
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 230000004043 responsiveness Effects 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 239000000758 substrate Substances 0.000 claims 1
- 239000000829 suppository Substances 0.000 claims 1
Claims (8)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24403600P | 2000-10-27 | 2000-10-27 | |
| US60/244,036 | 2000-10-27 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006122179/15A Division RU2416406C2 (en) | 2000-10-27 | 2006-06-20 | Method for treating neurological and neuro-psychological malfunctions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2003115622A true RU2003115622A (en) | 2004-10-27 |
| RU2286149C2 RU2286149C2 (en) | 2006-10-27 |
Family
ID=22921137
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2003115614/14A RU2003115614A (en) | 2000-10-27 | 2001-10-29 | METHOD FOR TREATING NEUROLOGICAL AND NEUROPSYCHOLOGICAL DISORDERS |
| RU2003115622/14A RU2286149C2 (en) | 2000-10-27 | 2001-10-29 | Method for treating patients for neurological and neuropsychological disorders |
| RU2006122179/15A RU2416406C2 (en) | 2000-10-27 | 2006-06-20 | Method for treating neurological and neuro-psychological malfunctions |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2003115614/14A RU2003115614A (en) | 2000-10-27 | 2001-10-29 | METHOD FOR TREATING NEUROLOGICAL AND NEUROPSYCHOLOGICAL DISORDERS |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006122179/15A RU2416406C2 (en) | 2000-10-27 | 2006-06-20 | Method for treating neurological and neuro-psychological malfunctions |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20040043919A1 (en) |
| EP (2) | EP1328270A2 (en) |
| JP (2) | JP2004512299A (en) |
| KR (2) | KR20040025875A (en) |
| CN (3) | CN1471392A (en) |
| AT (1) | ATE399008T1 (en) |
| AU (3) | AU2002227898A1 (en) |
| BR (2) | BR0114921A (en) |
| CA (3) | CA2689012A1 (en) |
| CY (1) | CY1108336T1 (en) |
| DE (1) | DE60134563D1 (en) |
| DK (1) | DK1328271T3 (en) |
| ES (1) | ES2309108T3 (en) |
| IL (4) | IL155116A0 (en) |
| NO (2) | NO20031849L (en) |
| PT (1) | PT1328271E (en) |
| RU (3) | RU2003115614A (en) |
| WO (2) | WO2002034243A2 (en) |
| ZA (2) | ZA200302590B (en) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ503359A (en) * | 1997-09-29 | 2002-02-01 | Point Therapeutics Inc | Method for proliferating haematopoietic cells in vitro in the absence of exogenous cytokines |
| US6979697B1 (en) * | 1998-08-21 | 2005-12-27 | Point Therapeutics, Inc. | Regulation of substrate activity |
| US6890904B1 (en) * | 1999-05-25 | 2005-05-10 | Point Therapeutics, Inc. | Anti-tumor agents |
| US7132104B1 (en) | 2000-10-27 | 2006-11-07 | Probiodrug Ag | Modulation of central nervous system (CNS) dipeptidyl peptidase IV (DPIV) -like activity for the treatment of neurological and neuropsychological disorders |
| ZA200302590B (en) * | 2000-10-27 | 2004-04-02 | Probiodrug Ag | Method for the treatment of neurological and neuropsychological disorders. |
| CN1990469A (en) | 2001-06-27 | 2007-07-04 | 史密丝克莱恩比彻姆公司 | Pyrrolidines as dipeptidyl peptidase inhibitors |
| PL372814A1 (en) | 2002-04-08 | 2005-08-08 | Torrent Pharmaceuticals Ltd. | Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidas inhibitors |
| AU2003265264A1 (en) * | 2002-07-09 | 2004-01-23 | Point Therapeutics, Inc. | Methods and compositions relating to isoleucine boroproline compounds |
| KR20050122220A (en) | 2003-03-25 | 2005-12-28 | 다케다 샌디에고, 인코포레이티드 | Dipeptidyl peptidase inhibitors |
| BRPI0410078A (en) | 2003-05-05 | 2006-05-16 | Probiodrug Ag | use of glutaminyl and glutamate cyclase effectors |
| KR20110059664A (en) | 2003-05-05 | 2011-06-02 | 프로비오드룩 아게 | Use of Effectors of Glutaminyl and Glutamate Cycase |
| WO2004103993A1 (en) | 2003-05-14 | 2004-12-02 | Syrrx, Inc. | Dipeptidyl peptidase inhibitors |
| BRPI0413452A (en) | 2003-08-13 | 2006-10-17 | Takeda Pharmaceutical | compound, pharmaceutical composition, kit, article of manufacture, and methods of inhibiting dpp-iv, therapeutic, and treating a disease state, cancer, autoimmune disorders, a condition and HIV infection |
| US7678909B1 (en) | 2003-08-13 | 2010-03-16 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| US7169926B1 (en) | 2003-08-13 | 2007-01-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| WO2005026148A1 (en) | 2003-09-08 | 2005-03-24 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| EP2289498A1 (en) | 2003-10-15 | 2011-03-02 | Probiodrug AG | Use of inhibitors of glutaminyl clyclase |
| US7732446B1 (en) | 2004-03-11 | 2010-06-08 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| CN102079743B (en) | 2004-03-15 | 2020-08-25 | 武田药品工业株式会社 | dipeptidyl peptidase inhibitor |
| JP2008501714A (en) | 2004-06-04 | 2008-01-24 | 武田薬品工業株式会社 | Dipeptidyl peptidase inhibitor |
| WO2006019965A2 (en) | 2004-07-16 | 2006-02-23 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| US20060063719A1 (en) * | 2004-09-21 | 2006-03-23 | Point Therapeutics, Inc. | Methods for treating diabetes |
| WO2006068978A2 (en) | 2004-12-21 | 2006-06-29 | Takeda Pharmaceutial Company Limited | Dipeptidyl peptidase inhibitors |
| GEP20135838B (en) | 2005-09-14 | 2013-06-10 | Takeda Pharmaceutical | Dipeptidyl peptidase inhibitors usage at diabetes treatment |
| CA2622642C (en) | 2005-09-16 | 2013-12-31 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| WO2007112347A1 (en) | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| AU2007235876A1 (en) | 2006-04-12 | 2007-10-18 | Probiodrug Ag | Enzyme inhibitors |
| US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
| TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
| US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
| RU2350331C1 (en) * | 2007-07-10 | 2009-03-27 | Государственное образовательное учреждение высшего профессионального образования "Мордовский государственный университет им. Н.П. Огарева" | Method of treatment of neurosis of obsessional conditions |
| RU2350330C1 (en) * | 2007-11-13 | 2009-03-27 | Государственное образовательное учреждение высшего профессионального образования "Мордовский государственный университет им. Н.П. Огарева" | Method of hysterical neurosis treatment |
| JO2870B1 (en) | 2008-11-13 | 2015-03-15 | ميرك شارب اند دوهم كورب | Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| US8455533B2 (en) | 2009-09-02 | 2013-06-04 | Merck Sharp & Dohme Corp. | Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
| CA2784799C (en) | 2009-12-30 | 2014-06-10 | Shanghai Fochon Pharmaceutical Co Ltd | Certain dipeptidyl peptidase inhibtors |
| WO2011103256A1 (en) | 2010-02-22 | 2011-08-25 | Merck Sharp & Dohme Corp. | Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes |
| EP2571876B1 (en) | 2010-05-21 | 2016-09-07 | Merck Sharp & Dohme Corp. | Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes |
| WO2013122920A1 (en) | 2012-02-17 | 2013-08-22 | Merck Sharp & Dohme Corp. | Dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| US9668969B1 (en) | 2012-02-22 | 2017-06-06 | Arturo Solis Herrera | Methods of using QIAPINE |
| WO2014018350A1 (en) | 2012-07-23 | 2014-01-30 | Merck Sharp & Dohme Corp. | Treating diabetes with dipeptidyl peptidase-iv inhibitors |
| CN107213465A (en) * | 2017-06-23 | 2017-09-29 | 武汉大学 | Inhibitors of dipeptidyl IV is preparing the application in preventing and treating the medicine of epilepsy |
| CN119380997B (en) * | 2024-12-27 | 2025-03-21 | 内蒙古医科大学附属医院(内蒙古自治区心血管研究所) | A neurological rehabilitation degree evaluation method and system |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US25023A (en) * | 1859-08-09 | Improved device for making electro-magnetic currents, constant or intermittent | ||
| US2961377A (en) * | 1957-08-05 | 1960-11-22 | Us Vitamin Pharm Corp | Oral anti-diabetic compositions and methods |
| US3174901A (en) * | 1963-01-31 | 1965-03-23 | Jan Marcel Didier Aron Samuel | Process for the oral treatment of diabetes |
| US3879541A (en) * | 1970-03-03 | 1975-04-22 | Bayer Ag | Antihyperglycemic methods and compositions |
| US3960949A (en) * | 1971-04-02 | 1976-06-01 | Schering Aktiengesellschaft | 1,2-Biguanides |
| CH602612A5 (en) * | 1974-10-11 | 1978-07-31 | Hoffmann La Roche | |
| US4935493A (en) * | 1987-10-06 | 1990-06-19 | E. I. Du Pont De Nemours And Company | Protease inhibitors |
| US5433955A (en) * | 1989-01-23 | 1995-07-18 | Akzo N.V. | Site specific in vivo activation of therapeutic drugs |
| DE4039415A1 (en) * | 1990-02-03 | 1991-08-08 | Boehringer Mannheim Gmbh | Recombinant proteins without N-terminal methionine gp. - which are G-CSF derivs. useful to treat cancer and in bone marrow transplants, etc. |
| US5462928A (en) * | 1990-04-14 | 1995-10-31 | New England Medical Center Hospitals, Inc. | Inhibitors of dipeptidyl-aminopeptidase type IV |
| IL106998A0 (en) * | 1992-09-17 | 1993-12-28 | Univ Florida | Brain-enhanced delivery of neuroactive peptides by sequential metabolism |
| IL111785A0 (en) * | 1993-12-03 | 1995-01-24 | Ferring Bv | Dp-iv inhibitors and pharmaceutical compositions containing them |
| US5705483A (en) * | 1993-12-09 | 1998-01-06 | Eli Lilly And Company | Glucagon-like insulinotropic peptides, compositions and methods |
| US5543396A (en) * | 1994-04-28 | 1996-08-06 | Georgia Tech Research Corp. | Proline phosphonate derivatives |
| US5512549A (en) * | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
| US5614379A (en) * | 1995-04-26 | 1997-03-25 | Eli Lilly And Company | Process for preparing anti-obesity protein |
| DE122010000020I1 (en) * | 1996-04-25 | 2010-07-08 | Prosidion Ltd | Method for lowering the blood glucose level in mammals |
| US6006753A (en) * | 1996-08-30 | 1999-12-28 | Eli Lilly And Company | Use of GLP-1 or analogs to abolish catabolic changes after surgery |
| US5827898A (en) * | 1996-10-07 | 1998-10-27 | Shaman Pharmaceuticals, Inc. | Use of bisphenolic compounds to treat type II diabetes |
| US6011155A (en) * | 1996-11-07 | 2000-01-04 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
| CA2819705C (en) * | 1998-02-02 | 2014-07-08 | Trustees Of Tufts College | Method of regulating glucose metabolism, and reagents related thereto |
| JP2002506075A (en) * | 1998-03-09 | 2002-02-26 | フォンダテッヒ・ベネルクス・ナムローゼ・フェンノートシャップ | Serine peptidase modulator |
| DE19823831A1 (en) * | 1998-05-28 | 1999-12-02 | Probiodrug Ges Fuer Arzneim | New pharmaceutical use of isoleucyl thiazolidide and its salts |
| DE19834591A1 (en) * | 1998-07-31 | 2000-02-03 | Probiodrug Ges Fuer Arzneim | Use of substances that decrease the activity of dipeptidyl peptidase IV to increase blood sugar levels, e.g. for treating hypoglycemia |
| AU3960400A (en) * | 1999-03-05 | 2000-09-28 | Molteni L. E C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A. | Use of metformin in the preparation of pharmaceutical compositions capable of inhibiting the enzyme dipeptidyl peptidase iv |
| US6172081B1 (en) * | 1999-06-24 | 2001-01-09 | Novartis Ag | Tetrahydroisoquinoline 3-carboxamide derivatives |
| US6107317A (en) * | 1999-06-24 | 2000-08-22 | Novartis Ag | N-(substituted glycyl)-thiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
| US6110949A (en) * | 1999-06-24 | 2000-08-29 | Novartis Ag | N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
| CA2400226C (en) * | 2000-03-31 | 2007-01-02 | Probiodrug Ag | Method for the improvement of islet signaling in diabetes mellitus and for its prevention |
| ZA200302590B (en) * | 2000-10-27 | 2004-04-02 | Probiodrug Ag | Method for the treatment of neurological and neuropsychological disorders. |
-
2001
- 2001-10-29 ZA ZA200302590A patent/ZA200302590B/en unknown
- 2001-10-29 WO PCT/EP2001/012479 patent/WO2002034243A2/en not_active Ceased
- 2001-10-29 AT AT01988583T patent/ATE399008T1/en active
- 2001-10-29 IL IL15511601A patent/IL155116A0/en unknown
- 2001-10-29 EP EP01988582A patent/EP1328270A2/en not_active Withdrawn
- 2001-10-29 KR KR10-2003-7005718A patent/KR20040025875A/en not_active Withdrawn
- 2001-10-29 AU AU2002227898A patent/AU2002227898A1/en not_active Abandoned
- 2001-10-29 AU AU2002221773A patent/AU2002221773B2/en not_active Ceased
- 2001-10-29 CN CNA01817857XA patent/CN1471392A/en active Pending
- 2001-10-29 US US10/415,263 patent/US20040043919A1/en not_active Abandoned
- 2001-10-29 PT PT01988583T patent/PT1328271E/en unknown
- 2001-10-29 BR BR0114921-0A patent/BR0114921A/en not_active Application Discontinuation
- 2001-10-29 CA CA002689012A patent/CA2689012A1/en not_active Abandoned
- 2001-10-29 CA CA002424475A patent/CA2424475A1/en not_active Abandoned
- 2001-10-29 JP JP2002537296A patent/JP2004512299A/en not_active Withdrawn
- 2001-10-29 KR KR10-2003-7005769A patent/KR20030096227A/en not_active Ceased
- 2001-10-29 CN CNB018180671A patent/CN1278683C/en not_active Expired - Fee Related
- 2001-10-29 RU RU2003115614/14A patent/RU2003115614A/en not_active Application Discontinuation
- 2001-10-29 CN CNA2006101219115A patent/CN101143217A/en active Pending
- 2001-10-29 DE DE60134563T patent/DE60134563D1/en not_active Expired - Lifetime
- 2001-10-29 RU RU2003115622/14A patent/RU2286149C2/en not_active IP Right Cessation
- 2001-10-29 CA CA2422889A patent/CA2422889C/en not_active Expired - Fee Related
- 2001-10-29 WO PCT/EP2001/012478 patent/WO2002034242A2/en not_active Ceased
- 2001-10-29 EP EP01988583A patent/EP1328271B1/en not_active Expired - Lifetime
- 2001-10-29 IL IL15515701A patent/IL155157A0/en unknown
- 2001-10-29 BR BR0114924-5A patent/BR0114924A/en not_active IP Right Cessation
- 2001-10-29 AU AU2177302A patent/AU2177302A/en active Pending
- 2001-10-29 ZA ZA200302394A patent/ZA200302394B/en unknown
- 2001-10-29 JP JP2002537297A patent/JP2004512300A/en active Pending
- 2001-10-29 DK DK01988583T patent/DK1328271T3/en active
- 2001-10-29 ES ES01988583T patent/ES2309108T3/en not_active Expired - Lifetime
-
2003
- 2003-03-27 IL IL155116A patent/IL155116A/en not_active IP Right Cessation
- 2003-04-24 NO NO20031849A patent/NO20031849L/en unknown
- 2003-04-25 NO NO20031867A patent/NO20031867L/en not_active Application Discontinuation
-
2006
- 2006-06-20 RU RU2006122179/15A patent/RU2416406C2/en not_active IP Right Cessation
-
2008
- 2008-09-11 CY CY20081100982T patent/CY1108336T1/en unknown
-
2009
- 2009-02-11 IL IL196994A patent/IL196994A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2003115622A (en) | METHOD FOR TREATING NEUROLOGICAL AND NEUROPSYCHOLOGICAL DISORDERS | |
| RU2006122179A (en) | METHOD FOR TREATING NEUROLOGICAL AND NEUROPSYCHOLOGICAL DISORDERS | |
| DE69834658D1 (en) | USE OF AMINOTHIOL COMPOUNDS FOR THE TREATMENT OF NERVE AND KIDNEY DISEASES AND THE MEDICAMENT TOXICITY | |
| ATE450269T1 (en) | PEPTIDE PYYÄ3-36Ü FOR THE TREATMENT OF METABOLIC DISEASES | |
| IL267381A (en) | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders | |
| DE60227658D1 (en) | METHOD FOR THE TREATMENT OF NEURODEEGENERATIVE, PSYCHIATRIC AND OTHER DISORDERS WITH DEACETYLASEINHIBITORS | |
| WO2007029249A3 (en) | Oligoribonucleotides and methods of use thereof for treatment of cardiovascular diseases | |
| IL157821A0 (en) | Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase iv | |
| MXPA04005790A (en) | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase. | |
| DE50115871D1 (en) | USE OF DIPEPTIDYLPEPTIDASE IV AND AMINOPEPTIDASE N INHIBITORS FOR THE TREATMENT OF ISCHEMIA-INDUCED NEURODEGENERATION | |
| WO2001045641A3 (en) | Inhibitors of thrombin induced platelet aggregation | |
| IL219857A0 (en) | Mitotic kinesin inhibitors, pharmaceutical compositions comprising them, uses thereof in the manufacture of a medicament for the treatment of disease or disorder in a human or animal that can be treated by inhibiting mitosis | |
| WO2005058233A3 (en) | Methods for treatment of acute pancreatitis | |
| ATE309795T1 (en) | ACETYLCHOLINESTERASE INHIBITORS FOR THE TREATMENT AND DIAGNOSIS OF BREATHING DISORDERS DURING SLEEP | |
| NZ544719A (en) | Combination of mGluR2 antagonist and aChE inhibitor for treatment of acute and/or chronic neurological disorders | |
| DE602007008855D1 (en) | USE OF (S) -ROSCOVITINE FOR THE PREVENTION AND / OR TREATMENT OF NEUROLOGICAL ILLNESSES | |
| ATE465743T1 (en) | OLIGONUCLEOTIDES FOR THE TREATMENT OF PROSTATE CANCER AND OTHER CANCER DISEASES | |
| WO2001041754A3 (en) | Inhibitors of collagen-induced platelet aggregation | |
| GB0130677D0 (en) | Medicaments and novel compounds | |
| TW200509929A (en) | Treatment of bipolar disorders and associated symptoms | |
| DE602005026276D1 (en) | MYRICITRINE COMPOUNDS FOR THE TREATMENT OF SLEEP DISORDERS | |
| ATE491715T1 (en) | OLIGORIBONUCLEOTIDES AND METHOD FOR USE THEREOF IN THE TREATMENT OF FIBROTIC DISEASES AND OTHER DISEASES | |
| WO2004062684A3 (en) | Treatment of thrombocytopenia with inhibitors of pacap | |
| WO2002062327A3 (en) | Method of treating neurological disorders using acetone derivatives | |
| ATE310509T1 (en) | METHOD OF TREATING A PATIENT IN NEED OF ANALGESIA |